Skip to main content

Market Overview

Recap: DexCom Q4 Earnings


Shares of DexCom (NASDAQ:DXCM) moved lower in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 20.87% over the past year to $0.91, which missed the estimate of $0.92.

Revenue of $568,900,000 higher by 22.93% from the same period last year, which beat the estimate of $552,230,000.


Dexcom Sees FY21 Sales $2.21B-$2.31B vs $2.33B Est.

How To Listen To The Conference Call

Date: Feb 11, 2021

Time: 04:30 PM

ET Webcast URL:


Company's 52-week high was at $456.23

Company's 52-week low was at $182.07

Price action over last quarter: Up 17.50%

Company Overview

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.


Related Articles (DXCM)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings